Evaluation of Hepatic/Renal and Splenic/Renal Echointensity Ratio Using Ultrasonography in Diabetic Nephropathy
- PMID: 37510145
- PMCID: PMC10377935
- DOI: 10.3390/diagnostics13142401
Evaluation of Hepatic/Renal and Splenic/Renal Echointensity Ratio Using Ultrasonography in Diabetic Nephropathy
Abstract
The objective of this study is to assess the hepatic/renal and splenic/renal echointensity ratios in ultrasonography in patients with and without diabetic nephropathy. This retrospective study included patients with diabetes mellitus who underwent ultrasound examinations at our hospital between January 2023 and May 2023. Ultrasound examinations were conducted using renal cortical echogenicity and corticomedullary differentiation by using B-mode ultrasonography. The hepatic/renal and splenic/renal echo intensity ratios were compared among study groups (diabetic patients with diabetic nephropathy and without nephropathy). The diabetic nephropathy group exhibited significantly higher right renal echointensity and left renal echointensity compared to the non-nephropathic group. Additionally, the splenic/renal echointensity ratio and hepatic/renal echointensity ratio were significantly lower in the diabetic nephropathy group. Urinary microalbumin levels were significantly correlated with right renal echointensity (r = 0.65, p < 0.001) and left renal echointensity (r = 0.69, p < 0.001). There was also a significant inverse correlation between the urinary albumin and splenic/renal echointensity ratio (r = -0.58, p < 0.001). Ultrasonography, specifically the assessment of hepatic/renal and splenic/renal echointensity ratios, shows promise as a noninvasive and cost-effective method for evaluating morphological changes in the kidneys in patients with diabetic nephropathy. These findings suggest that ultrasonography can be a valuable tool for monitoring the progression of diabetic nephropathy and contributing to its early detection and management.
Keywords: diabetic nephropathy; echointensity; type 2 diabetes mellitus; ultrasonography.
Conflict of interest statement
The author declares no conflict of interest.
Figures
Similar articles
-
Resistive Index of Intrarenal Artery in Evaluation of Diabetic Nephropathy.Bangladesh Med Res Counc Bull. 2015 Dec;41(3):125-130. doi: 10.3329/bmrcb.v41i3.29888. Bangladesh Med Res Counc Bull. 2015. PMID: 29870167
-
Investigation of angiotensin-1 converting enzyme 2 gene (G8790A) polymorphism in patients of type 2 diabetes mellitus with diabetic nephropathy in Pakistani population.PLoS One. 2022 Feb 17;17(2):e0264038. doi: 10.1371/journal.pone.0264038. eCollection 2022. PLoS One. 2022. PMID: 35176079 Free PMC article.
-
Increased muscle echointensity correlates with clinical disability and muscle strength in chronic inflammatory demyelinating polyneuropathy.Eur J Neurol. 2021 May;28(5):1698-1705. doi: 10.1111/ene.14716. Epub 2021 Jan 27. Eur J Neurol. 2021. PMID: 33404183
-
An Investigation on the Efficacy of Glucagon-Like Peptide 1 Receptor Agonists Drugs in Reducing Urine Albumin-to-Creatinine Ratio in Patients With Type 2 Diabetes: A Potential Treatment for Diabetic Nephropathy.Cureus. 2023 Mar 20;15(3):e36438. doi: 10.7759/cureus.36438. eCollection 2023 Mar. Cureus. 2023. PMID: 37090383 Free PMC article. Review.
-
Treatment of diabetic nephropathy with angiotensin II receptor antagonist.Clin Exp Nephrol. 2003 Mar;7(1):1-8. doi: 10.1007/s101570300000. Clin Exp Nephrol. 2003. PMID: 14586737 Review.
Cited by
-
The Potential Use of Targeted Proteomics and Metabolomics for the Identification and Monitoring of Diabetic Kidney Disease.J Pers Med. 2024 Oct 11;14(10):1054. doi: 10.3390/jpm14101054. J Pers Med. 2024. PMID: 39452561 Free PMC article. Review.
-
Advances in Theranostic Approaches and Emerging Biomarkers of Diabetes Mellitus.Diagnostics (Basel). 2024 Oct 3;14(19):2207. doi: 10.3390/diagnostics14192207. Diagnostics (Basel). 2024. PMID: 39410611 Free PMC article.
References
-
- Safiri S., Kolahi A.A., Naghavi M. Global, regional and national burden of bladder cancer and its attributable risk factors in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease study 2019. BMJ Glob. Health. 2021;6:e004128. doi: 10.1136/bmjgh-2020-004128. - DOI - PMC - PubMed
-
- Centers for Disease Control and Prevention . National Diabetes Statistics Report, 2017-Estimates of Diabetes and Its Burden in the United States Background. Centers for Disease Control and Prevention (CDC); Atlanta, GA, USA: 2017.
-
- Lindström J., Ilanne-Parikka P., Peltonen M., Aunola S., Eriksson J.G., Hemiö K., Hämäläinen H., Härkönen P., Keinänen-Kiukaanniemi S., Laakso M., et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: Follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368:1673–1679. doi: 10.1016/S0140-6736(06)69701-8. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources